文献速递糖尿病肥胖与代谢综合征

替尔泊肽治疗MASH中代谢与组织学应答的关系:SYNERGY-NASH试验参与者水平探索性分析

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究为52周随机双盲安慰剂对照2期SYNERGY-NASH试验的参与者水平事后分析,纳入190例MASH伴2/3期纤维化患者,评估替尔泊肽(5、10、15 mg每周一次)治疗下代谢变化与组织学应答的关系。结果显示,MASH缓解和纤维化改善的应答者体重下降、HbA1c降低及肝脏脂肪正常化程度均显著优于无应答者,且肝脏脂肪正常化是两种组织学应答的显著中介因素。

要点

  • MASH缓解和纤维化改善的应答者体重下降幅度显著大于无应答者。
  • 应答者HbA1c降幅及肝脏脂肪、脂肪组织胰岛素敏感性改善更显著。
  • 肝脏脂肪正常化是MASH缓解和纤维化改善的显著中介因素。

核心结论

  • MASH缓解和纤维化改善与体重下降、血糖控制改善及肝脏脂肪正常化相关。
  • 替尔泊肽治疗带来的体重下降和代谢改善可能有助于MASH疾病修饰。

研究设计与样本

  • 52周、双盲、随机、安慰剂对照的2期SYNERGY-NASH试验(NCT04166773)的参与者水平事后分析。
  • 纳入190例MASH伴2/3期纤维化患者,随机接受替尔泊肽5、10或15 mg或安慰剂每周一次。
  • 代谢变化在154例完成治疗的研究参与者中按组织学终点应答者与无应答者评估。

主要发现

  • 基线时59%患有2型糖尿病,平均BMI为35.7 kg/m2。
  • MASH缓解应答者体重下降-16.0% vs 无应答者-7.0%(P < 0.001)。
  • 纤维化改善应答者体重下降-13.6% vs 无应答者-9.8%(P = 0.023)。
  • MASH应答者HbA1c下降-1.2% vs 无应答者-0.6%(P < 0.001);纤维化应答者-1.2% vs 无应答者-0.7%(P = 0.004)。
  • MASH应答者肝脏脂肪和脂肪组织胰岛素敏感性指标(脂肪组织胰岛素抵抗指数和脂联素)改善更显著(P < 0.001)。

临床怎么用

  • 在替尔泊肽治疗MASH伴2/3期纤维化患者时,体重下降和血糖控制改善与组织学应答相关。
  • 肝脏脂肪正常化可能是治疗应答的重要中介指标,可作为监测参考。

局限性

  • 为事后探索性分析,结果需进一步验证。
  • 代谢变化分析仅基于154例完成治疗的研究参与者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the relationship between metabolic and histological responses in a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH). RESEARCH DESIGN AND METHODS: This is a participant-level post hoc analysis of the 52-week, double-blind, randomized, placebo-controlled SYNERGY-NASH trial (NCT04166773). Participants (n = 190) with MASH and stage 2/3 fibrosis were randomly assigned to receive tirzepatide (5, 10, or 15 mg) or placebo once weekly. The primary end point was MASH resolution without worsening of fibrosis. Secondary end points included fibrosis improvement by at least one stage without worsening of MASH. Metabolic changes were evaluated in responders and nonresponders for histological end points in 154 participants who completed the study on treatment. RESULTS: At baseline, 59% had type 2 diabetes and mean BMI was 35.7 kg/m2. Compared with nonresponders, greater body weight reductions were observed in responders for MASH resolution (-16.0% vs. -7.0%; P < 0.001) and for fibrosis improvement (-13.6% vs. -9.8%; P = 0.023). Reductions in HbA1c were greater for MASH responders (-1.2% vs. -0.6%; P < 0.001) and fibrosis responders (-1.2% vs. -0.7%; P = 0.004) than for nonresponders. Compared with nonresponders, greater improvements in liver fat and measures of adipose tissue insulin sensitivity (adipose tissue insulin resistance index and adiponectin) were observed with MASH responders (P < 0.001). In causal mediation analyses, normalization of liver fat was a significant mediator of both MASH resolution and fibrosis improvement. CONCLUSIONS: In this post hoc exploratory analysis, MASH resolution and fibrosis improvement were associated with body weight reduction, improved glycemic control, and normalization of liver fat. Weight reduction and metabolic improvements with tirzepatide treatment potentially contributed to disease modification in MASH.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Caussy C, Cusi K, Rosenstock J, et al. Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. Diabetes Care. 2025. PMID: 41066427. doi:10.2337/dc25-1306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。